Close

Anti-IL13Rα2 (IL13 mutein ((E13Y))-Megf10 CAR-MA (CARMA-W0988)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-IL13Rα2 chimeric antigen receptor (CAR) is constructed for the engineering of macrophage cells to target human IL13Rα2 and induce target cell phagocytosis. The macrophage cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-IL13Rα2 antibody (IL13 mutein ((E13Y)) linked to Megf10 signaling domains. The vector product was designed for the treatment of Glioma, GBM.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • IL13Rα2
  • Cell Type
  • Macrophage
  • Targeting Diseases
  • Glioma, GBM
  • Vector Name
  • pCDCAR1
  • Vector length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Size
  • 10 µg
  • Storage
  • Store at -20°C for long term.

CAR Components

  • Promoter
  • EF1a
  • scFv
  • IL13 mutein ((E13Y)
  • Hinge
  • CD8
  • TM
  • CD8
  • ICD
  • Megf10
  • Marker
  • GFP or N/A
  • Receptor Construction
  • scFv-hinge(CD8)-TM(CD8)-ICD(Megf10)
  • Discription of Signaling Cassetes
  • Megf10:
    Megf10 is used as the CAR intracellular signaling domain. As a phagocytosis receptor, Megf10 has cytosolic Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) that are phosphorylated by Src family kinases. Based on this mechanism, Megf10 signaling can induce macrophage phagocytosis which has been demonstrated in the published article.
    It is a membrane receptor involved in phagocytosis by macrophages and astrocytes of apoptotic cells. It's a receptor for C1q, an eat-me signal, that binds phosphatidylserine expressed on the surface of apoptotic cells

Target

  • Target
  • IL13Rα2
  • Target Species
  • Human
  • Clone
  • IL13 mutein ((E13Y)
  • Host
  • Human
  • Gene Name
  • Interleukin 13 receptor subunit alpha 2
  • Introduction
  • The protein encoded by this gene is closely related to Il13RA1, a subuint of the interleukin 13 receptor complex. This protein binds IL13 with high affinity, but lacks cytoplasmic domain, and does not appear to function as a signal mediator. It is reported to play a role in the internalization of IL13.
  • Alternative Names
  • CT19; IL-13R; IL13BP; CD213A2; IL13RA2; Interleukin 13 receptor subunit alpha 2; IL13Rα2

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-IL13Rα2 (IL13 mutein ((E13Y)) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 (CARMA-W0988). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.